Unknown

Dataset Information

0

Chromatin structure predicts epigenetic therapy responsiveness in sarcoma.


ABSTRACT: To formally explore the potential therapeutic effect of histone deacetylase inhibitors (HDACI) and DNA-methyltransferase inhibitors (DNA-MI) on sarcomas, we treated a large sarcoma cell line panel with five different HDACIs in the absence and presence of the DNA-MI decitabine. We observed that the IC(50) value of each HDACI was consistent for all cell lines whereas decitabine as a single agent showed no growth inhibition at standard doses. Combination HDACI/DNA-MI therapy showed a preferential synergism for specific sarcoma cell lines. Subsequently, we identified and validated (in vitro and in vivo) a two-gene set signature (high CUGBP2; low RHOJ) that associated with the synergistic phenotype. We further uncover that the epigenetic synergism leading to specific upregulation of CDKI p21 in specific cell lines is a function of the differences in the degree of baseline chromatin modification. Finally, we show that these chromatin and gene expression patterns are similarly present in the majority of high-grade primary sarcomas. Our results provide the first demonstration of a gene set that can predict responsiveness to HDACI/DNA-MI and links this responsiveness mechanistically to the baseline chromatin structure.

SUBMITTER: Mills J 

PROVIDER: S-EPMC3075587 | biostudies-literature | 2011 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Chromatin structure predicts epigenetic therapy responsiveness in sarcoma.

Mills Joslyn J   Hricik Todd T   Siddiqi Sara S   Matushansky Igor I  

Molecular cancer therapeutics 20110107 2


To formally explore the potential therapeutic effect of histone deacetylase inhibitors (HDACI) and DNA-methyltransferase inhibitors (DNA-MI) on sarcomas, we treated a large sarcoma cell line panel with five different HDACIs in the absence and presence of the DNA-MI decitabine. We observed that the IC(50) value of each HDACI was consistent for all cell lines whereas decitabine as a single agent showed no growth inhibition at standard doses. Combination HDACI/DNA-MI therapy showed a preferential s  ...[more]

Similar Datasets

| S-EPMC2734077 | biostudies-literature
| S-EPMC5555411 | biostudies-other
| S-EPMC7768195 | biostudies-literature
| S-EPMC5760470 | biostudies-other
| S-EPMC8085025 | biostudies-literature
| S-EPMC4017678 | biostudies-literature
2022-04-26 | GSE180516 | GEO
| S-EPMC8770413 | biostudies-literature
| S-EPMC3597696 | biostudies-literature
| S-EPMC5291540 | biostudies-literature